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Introduction
Late onset Alzheimer's disease (AD) is the most common form of dementia in the aging population accounting for 60-80% of all cases (Alzheimer's Association Report, 2012) . AD is a progressive neurodegenerative disorder characterized by plaques composed of β-amyloid protein (Aβ) surrounded by dystrophic neurites and neurofibrillary tangles (Alzheimer's Association Report, 2012). These histopathological hallmarks are accompanied by synaptic and neuronal loss, cerebral atrophy, cerebral amyloid angiopathy (Vinters, 2015) , and inflammatory processes (Heneka et al., 2015) . The progression of neurodegeneration in AD patients results in memory impairment and decline in other cognitive abilities often combined with non-cognitive symptoms including mood and personality changes (Alzheimer's Association Report, 2012) .
A meta-analysis of genome-wide association studies identified 11 new loci associated with AD, among which PTK2B was one of the most significant (Lambert et al., 2013) . This finding was replicated in other studies (Jiao et al., 2015) , which suggested that PTK2B was associated with hippocampal sclerosis (Beecham et al., 2014) , disease progression , and cognitive decline (Nettiksimmons et al., 2016) . PTK2B encodes Pyk2, a Ca 2+ -activated non-receptor tyrosine kinase closely related to focal adhesion kinase (FAK) (Lev et al., 1995; Sasaki et al., 1995; Avraham et al., 1995) . The sensitivity of Pyk2 to increases in intracellular free Ca 2+ distinguishes it from other tyrosine kinases. In response to Ca 2+ Pyk2 is autophosphorylated on Tyr-402, which recruits and activates Src-family kinases (SFKs), (Dikic et al., 1996; Walkiewicz et al., 2015) . In turn, SFKs phosphorylate other residues in Pyk2 and associated proteins, and initiate multiple signaling pathways. The striatal-enriched protein tyrosine phosphatase (STEP), which is enriched in forebrain regions, dephosphorylates Pyk2 (Xu et al., 2012) . Pyk2 plays a role in several cancers and specific inhibitors are under development (Lipinski & Loftus, 2010) . Although many cell types express Pyk2, it is highly enriched in forebrain neurons (Menegon et al., 1999) where it is activated by neuronal activity and excitatory neurotransmission (Corvol et al., 2005; Huang et al., 2001; Siciliano et al., 1996) . Pyk2 regulates NMDA receptor function and is involved in synaptic plasticity (Huang et al., 2001; Bartos et al., 2010; Hsin et al., 2010) . Our recent work with Pyk2 knockout mice shows that Pyk2 in the hippocampus is essential for spatial memory and long-term potentiation (Giralt et al., 2017) . It also modulates the density and morphology of spines and the organization of post-synaptic regions (Giralt et al., 2017) . Interestingly, heterozygous Pyk2 knockout mice have memory and hippocampal long term potentiation (LTP) deficits similar to homozygous mice and decreased Pyk2 levels contribute to the hippocampal phenotype of a Huntington's disease mouse model (Giralt et al., 2017) . Thus, partial loss of Pyk2 function in the hippocampus has clear functional consequences. The production of Aβ, a particular proteolytic fragment of amyloid precursor protein (APP), is a hallmark of AD (Benilova et al., 2012) . It can form plaques and neurotoxic oligomers of various conformation and complexity (Mucke & Selkoe, 2012) . Aβ oligomers can bind to cellular prion protein (PrPc) (Lauren et al., 2009 ) and signaling by PrPc and metabotropic glutamate receptor 5 (mGluR5), which includes Pyk2 activation, is disrupted by Aβ oligomers (Haas & Strittmatter, 2016) . Another key molecular abnormality in AD is aberrant phosphorylation of Tau (Mandelkow & Mandelkow, 2012) . In Drosophila the single orthologue of Pyk2 and FAK interacts with Tau and appears to suppress its toxicity (Dourlen et al., 2016) . Moreover, in human AD brain hyperphosphorylated Tau and Pyk2 are colocalized (Dourlen et al., 2016) . Finally, inhibitors of STEP enhance Pyk2 phosphorylation in vivo and improve some cognitive deficits in 3xTg-AD mouse model of AD . Thus, the PTK2B locus is reliably associated with AD risk and experimental evidence suggests that Pyk2 has the potential to play a role in the course of the disease, which remains to be characterized.
Here we investigated the role of Pyk2 in the 5XFAD mouse model in which Aβ production is strongly increased, due to expression of mutated forms of human APP and presenilin-1 (Oakley et al., 2006) . These mice display age-dependent plaque development with features of AD including hippocampal-related cognitive deficits, neuroinflammation, neuronal loss, and synaptic degeneration (Oakley et al., 2006) . We tested the potential role of Pyk2 in this model by genetic deletion and adeno-associated virus (AAV) mediated overexpression. Although Pyk2 levels were not changed in samples from AD or 5XFAD mice, Pyk2 autophosphorylation was reduced in 5XFAD mice indicating a decreased function. Deletion of the Pyk2 gene did not markedly alter the phenotype of 5XFAD mice, whereas overexpression of Pyk2 in the hippocampus rescued some behavioral alterations with correction of deficit in synaptic proteins and Src.
Materials and methods

Mouse lines
5XFAD mice expressing human amyloid precursor protein 695 (APP695) with Swedish, London, and Florida mutations, and M146L/ L286V presenilin-1, under the control of the murine Thy-1 promoter (Oakley et al., 2006) , were crossed with Pyk2 −/− mice (Giralt et al., 2016) . Genotyping (Oakley et al., 2006; Giralt et al., 2016) 
Human samples
Prefrontal tissue was from patients with AD Braak grades V-VI (3 females, 2 males, age, 87.6 ± 2.8 years; post-mortem intervals, 8.0 ± 2.4 h, means ± SEM) and control cases (4 females, 1 male, age, 87.2 ± 3.3 years; post-mortem intervals, 7.2 ± 0.9 h) were obtained from the Center of Cognitive Neurology, Lariboisière Hospital (Paris France) with approval by the Ethical Committee of Paris Diderot University Hospitals (CEERB Bichat University Hospital, Paris, France). Hippocampal samples were obtained from two different sources: i) The Lille Neurobank (fulfilling criteria of the French law on biological resources and declared to competent authority under the number DC-2008-642) with donor consent, data protection and ethical committee review, samples managed by the CRB/CIC1403 Biobank, BB-0033-00030, patients with AD Braak stage VI (3 females, 2 males, age, 75.4 ± 3.8 years, post-mortem interval 17.4 ± 3.8 h, means ± SEM) and controls (2 females, 3 males, age, 50.8 ± 9.7 years, post-mortem interval 16.6 ± 4.0 h); ii) the Banc de Teixits Neurològics (Biobanc-HC-IDIBAPS) with the approval of the ethical committee of the University of Barcelona with the reference: IRB00003099, patients with AD Braak grades V-VI (11 females, 4 males, age, 84.7 ± 1.8 years; post-mortem intervals, 9 ± 3.4 h, means ± SEM) and control cases (6 females, 4 males, age, 84.2 ± 3.4 years; post-mortem intervals, 12 ± 1 h). The 2 sets of samples were analyzed separately, results expressed as a % of the control mean in the series and data being similar they were pooled for final comparison (1 aberrant point was discarded). All the patients had an history of progressive dementia and satisfied National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders (NINCDS-ADRDA) criteria for probable AD (McKhann et al., 1984) and satisfied neuropathological criteria for AD (Paquet et al., 2012) . This research project was.
Tissue preparation and immunoblotting
Brains were quickly removed from mice deeply anesthetized in a CO 2 chamber, hippocampus dissected out, frozen in dry ice, and stored at −80°C until use. Briefly, tissue was sonicated in 250 μL of lysis buffer (phosphate buffered saline [PBS, NaCl, 137 mM, KCl, 2.7 mM, Na 2 HPO4, 10 mM, KH2PO 4 , 1.8 mM, pH 7.5] with 1% Nonidet P40 [vol/vol] , 1 g/L sodium dodecylsulfate (SDS), 5 g/L sodium deoxycholate, protease inhibitors 1:1, 000 [Sigma] , and 2 g/L sodium orthovanadate), centrifuged at 15, 000 ×g for 20 min and 15 mg protein from the supernatant were analyzed by SDS-polyacrylamide gel electrophoresis (7.5 g/L acrylamide) and transferred to nitrocellulose membranes (Millipore, Bedford, MA). Human tissue was analyzed similarly. Membranes were blocked in TBS-T (150 mM NaCl, 20 mM TrisHCl, pH 7.5, 0.5 mL/L Tween 20) with 50 g/L non-fat dry milk and 50 g/L BSA, and incubated overnight at 4°C with shaking, in the presence of primary antibodies in PBS with 0.2 g/L NaN 3 (Supplementary Table 1 ). After several washes in TBS-T, blots were incubated with antirabbit IgG IRdye800CW-coupled or antimouse IgG IRdye700DXcoupled antibodies (1/2, 000, Rockland Immunochemicals, USA) and signal detected by the Odyssey Li-Cor and analyzed using ImageJ.
Immunofluorescence
For immunofluorescence (IF), deeply anesthetized mice (pentobarbital 60 mg/kg) were intracardially perfused with a paraformaldehyde solution (40 g/L paraformaldehyde in 0.12 M sodium phosphate, pH 7.2). Brains were removed and post-fixed overnight in the same solution, cryoprotected with 300 g/L sucrose in PBS with 0.2 g/L NaN 3 and frozen in dry ice-cooled isopentane. Serial coronal 30-μm cryostat sections were free-floating incubated as described (Giralt et al., 2017) . They were washed three times in PBS, permeabilized 15 min at RT in PBS containing 3 mL/L Triton X-100 and 30 mL/L goat serum (Pierce Biotechnology, Rockford, IL). After these washes, brain sections were incubated overnight at 4°C with primary antibodies (antibodies sources and dilutions in Supplementary Table 1) in PBS with 0.2 g/L NaN 3 . After three washes sections were incubated 2 h at RT with fluorescent secondary 488 anti-rabbit or 555 anti-mouse antibodies (1:250, Molecular Probes, Sunnyvale, CA). No signal was detected in control sections incubated in the absence of primary antibody. Confocal images were acquired with a Leica Confocal SP5-II (63× numerical aperture lens, 5× digital zoom, 1-Airy unit pinhole, 4-frame averaging per z-step, zstacks every 2 μm, 1, 024 × 1, 024 pixel resolution). PSD-95-and synaptophysin-1-positive clusters (Prange et al., 2004) were analyzed with NIH ImageJ, in at least 3 slices per mouse and up to 3 CA1 stratum radiatum images per slice. Stained β-amyloid plaques were photographed from the entire hippocampus (three slices per mouse) with a DM6000-2 microscope (Leica), analyzed with ImageJ and counted manually in CA1, CA3, and DG.
Proximity ligation assay
Proximity ligation assay (PLA) was carried out using Duolink® detection kit (Sigma) according to manufacturer's protocol. Floating-sections were incubated with primary Pyk2 and β-amyloid antibodies overnight at 4°C. PLA probes anti-mouse PLUS and anti-rabbit MINUS were added overnight at 4°C. Sections were washed in TBS + 0.1% Tween 20 and incubated in Duolink® ligation solutions and ligase for 1 h at 37°C. Next, the signal was amplified by the addition of Duolink® amplification and polymerase for 2.5 h at 37°C. The detection of the red fluorophore (excitation 594 nm, emission 624 nm) was used. Nuclei were stained with DAPI using mounting media provided in the kit. As a negative control, one of the two primary antibodies was omitted.
Behavioral tests
Mouse anxiety was analyzed in a plastic elevated plus-maze made with two opposing 30 × 8 cm open arms, and two opposing 30 × 8 cm arms enclosed by 15 cm-high walls placed 50 cm above the floor and dimly lit (60 lx). Each mouse was placed in the central square, facing an open arm and the time spent in the open arms, which normally correlates with low levels of anxiety, measured for 5 min.
Spontaneous locomotor activity was measured in dim lit (60 lx) open field white square arena (40 × 40 × 40 cm in length, width, and height respectively). Animals were placed at the center and allowed to explore freely for 30 min. Spontaneous locomotor activity was measured.
Novel object recognition was tested in a dimly lit (60 lx) 40 × 40 × 40 cm white square arena. Mice were first habituated to the arena in the absence of objects (3 days, 15 min/day). On the fourth day, two similar objects were presented to each mouse during 10 min (A'A′′ condition) after which they were returned to their home cage for 15 min. After that, the animals were placed in the arena where they were tested during 5 min with a familiar and a new object (A′ B condition; shortterm memory, STM), and then returned to their home cage. Twentyfour hours later, the same animals were re-tested for 5 min in the arena with a familiar and a new object (BC condition; long-term memory, LTM). The object preference was measured as the time spent exploring each object × 100/time exploring both objects.
The passive avoidance (light-dark) paradigm was conducted in a 2-compartment box, where 1 compartment was dimly lit (20 lx) and the other brightly lit (200 lx). Both chambers were connected by a door (5 cm × 5 cm). During training, mice were placed into the aversive brightly lit compartment, and upon the entry into the preferred dimly lit compartment (with all 4 paws inside the dark chamber), they received a mild foot shock (2-s foot shock, 1 mA intensity). The latency of mice to enter into the dark chamber was recorded. Twenty seconds after receiving the foot shock, mice were returned to the home cage until testing 24 h later (long-term memory). For this retention test, mice were returned to the brightly lit compartment and the latency to enter the shock-paired compartment (dark chamber) was measured (10-min time cutoff).
For all tests at the end of each trial, any defecation was removed and the apparatus was wiped with 30% ethanol. Animals were tracked and recorded with SMART junior software (Panlab, Spain).
Viral constructs and stereotactic injection
For Pyk2 overexpression we used adeno-associated viruses (AAV) expressing Pyk2 (Giralt et al., 2017 ) (AAV1-CamKIIα (0.4)-GFP-2A-mPTK2B; Vector Biolabs Malvern, PA, USA) or, as control, AAVs expressing GFP (AV-9-PV1917, AAV9·CamKIIα (0.4).eGFP·WPRE.rBG (AAV-GFP) from Perelman School of Medicine, University of Pennsylvania). Mice were anesthetized with pentobarbital (30 mg/kg) and bilaterally injected with AAV-GFP or AAV-Pyk2 (2.06 × 10 9 GS) in the dorsal hippocampus at the following coordinates from the bregma (millimeters); anteroposterior, −2.0; lateral, ± 1.5; and dorsoventral, −1.4 and − 2.0. AAVs were injected over 2 min, leaving the cannula in place for 5 additional minutes to ensure complete diffusion of the viruses, and then slowly retracted from the brain. The animals were monitored for 2 h after administration and then returned to the housing facility for 21 days before behavioral assessment and brain analysis.
Statistical analysis
Analysis was done using GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolla California USA. Data are expressed as mean + SEM. Normal distribution was tested with d'Agostino and Pearson omnibus, Shapiro-Wilk, and Kolmogorov-Smirnov normality tests. If at least one of them was passed, statistical analysis was performed using two-tailed Student's t-test or ANOVA and Holm-Sidak's post hoc test. Otherwise non-parametric Mann and Whitney or KruskalWallis' and Dunn's tests were used. p < 0.05 was considered as statistically significant.
Results
Pyk2 expression and phosphorylation in patients and 5XFAD mice
We first examined Pyk2 protein levels in post-mortem prefrontal and hippocampal human tissue. In the two regions Pyk2 levels did not differ between AD patients and controls ( Fig. 1A-B) . The detection of the autophosphorylated form of Pyk2 in the human brain samples, either in patients or in controls, was variable from one batch to the other, presumably due to post-mortem endogenous dephosphorylation (not shown) making this measurement unreliable. We then analyzed the hippocampus of 8-month-old 5XFAD mice, at an age at which they have a clear phenotype (Oakley et al., 2006; Schneider et al., 2014) to be comparable to the human samples. Total Pyk2 levels were similar in wild type (WT) and 5XFAD mice, whereas pTyr402-Pyk2 levels were lower in 5XFAD than in WT mice ( Fig. 1C-D) . Since autophosphorylation at Tyr402 is a key step in the activation of Pyk2 (Dikic et al., 1996; Girault et al., 1999; Park et al., 2004) this result indicated a functional alteration of this kinase. In contrast, in 3-month-old 5XFAD mice, both total Pyk2 and pTyr402-Pyk2 levels were similar to WT (Fig. 1C , E). Our results show that Pyk2 levels were normal in AD patients and 5XFAD mice but that its autophosphorylation was decreased in 8-month 5XFAD mice.
Pyk2 is co-localized with Aβ in 5XFAD mice
We compared Pyk2 localization in the hippocampus of 5XFAD mice with Aβ immunoreactivity and plaques. Aβ-positive plaques were negative for Pyk2 ( Fig. 2A-C) . In contrast, Pyk2 and Aβ-like immunofluorescence displayed a significant degree of colocalization in neuropil zones devoid of amyloid plaques (Fig. 2D) , as supported by the calculation of the Manders' colocalization coefficient (Manders et al., 1992) in the 3 hippocampal regions studied (Fig. 2E ). To corroborate this apparent colocalization, we used an in situ proximity ligation assay (PLA). Hippocampal sections of 5XFAD mice were probed with Pyk2 and β-amyloid antibodies followed by hybridization with secondary antibodies coupled to oligonucleotides that hybridize together if the distance between the two target proteins is < 40 nm. The interaction between Pyk2 and β-amyloid was detected as red dots in all hippocampal regions (Fig. 2F, right panels) . As a negative control, only one primary antibody was added and amplification of the signal was not detected (Fig. 2F, left panels) . These results provide evidence for some degree of colocalization of Pyk2 and Aβ immunoreactivity in the neuropil of 5XFAD mice.
Pyk2 genetic deletion does not change the behavioral phenotype of 5XFAD mice
We reasoned that if Pyk2 played a role in the pathogenesis of the 5XFAD model, its deletion should delay or modify their phenotype. We crossed 5XFAD mice with Pyk2 −/− mice and studied their phenotype at 8-month, an age at which these mice have a clear but not severe behavioral phenotype (Grinan-Ferre et al., 2016) . We focused on a single time point, since the relatively mild phenotype was appropriate to detect either improvement or worsening of the disease. We compared WT and 5XFAD mice, expressing or not Pyk2 (Fig. 3A) . All mice displayed similar spontaneous locomotor activity (Fig. 3B ). To study memory capabilities, since Pyk2 deletion by itself impairs hippocampus-dependent spatial memory (Giralt et al., 2017) , we used the novel object recognition test, which was not impaired in Pyk2 −/− mice ( Fig. 3C-D ).
Twenty min after training, mice of all genotypes preferentially explored the novel object (short-term memory, Fig. 3C ). One day after object displacement, WT and Pyk2 −/− mice still explored more the new object than the familiar one (Fig. 3D ). In contrast this preference was completely absent in both 5XFAD and 5XFAD x Pyk2 −/− mice, revealing a specific long-term memory deficit in 5XFAD, which was not modified in the absence of Pyk2 (Fig. 3D) . We next examined associative memory in the passive avoidance task (Fig. 3E ). Latency to step-through during the training session was similar in the 4 genotypes. In the testing session, 24 h later, although all mice showed a pronounced increase in the latency to enter the dark compartment, this latency was lower in 5XFAD, Pyk2 −/− , and 5XFAD x Pyk2 −/− mice than in WT littermates (Fig. 3E ).
These results showed that Pyk2 deletion induced by itself a deficit in the passive avoidance performance, and that this deficit was not additive with the alterations observed in 5XFAD mice. Finally, we used the elevated plus-maze to evaluate anxiety, which is decreased in 5XFAD mice (Schneider et al., 2014; Grinan-Ferre et al., 2016) . (Fig. 3F) . Pyk2 −/− mice did not differ from WT mice, nor 5XFAD
x Pyk2 −/− from 5XFAD (Fig. 3F) . Taken together these results confirm the existence of behavioral alterations in 5XFAD mutant mice, which were not modified in the absence of Pyk2.
Pyk2 knockout induces only minor changes in 5XFAD mice neuropathology
The number of synapses decreases in 5XFAD mice in correlation with cognitive decline (Grinan-Ferre et al., 2016; Hongpaisan et al., 2011; Shao et al., 2011) . To examine whether this alteration was modified in the absence of Pyk2, we measured immunoreactive puncta for PSD-95 and synaptophysin, which are post-and pre-synaptic markers, respectively, and which have been previously used in AD mouse models as an indication of the number of synapses (Grinan-Ferre et al., 2016; Hongpaisan et al., 2011; Shao et al., 2011) . We analyzed these two markers in CA1 stratum radiatum of 8-month mice (Fig. 4A-D) . PSD-95-positive puncta were decreased in CA1of Pyk2 Fig. 4A-B) . The lack of additivity of the defect on the double mutants suggested that the post-synaptic alteration of PSD-95 might depend on common molecular dysfunction in the two mutant mice. In contrast, synaptophysin-positive puncta were decreased in 5XFAD but not Pyk2 −/− hippocampus ( Fig. 4C-D) , consistent with the predominantly post-synaptic phenotype in Pyk2 KO mice (Giralt et al., 2017) . To test whether the lack of Pyk2 can exacerbate or ameliorate β-amyloidosis in 8-month 5XFAD mice we then counted the number of Aβ-immunoreactive plaques in three regions of dorsal hippocampus (CA1, CA3, and dentate gyrus, DG) in 5XFAD and 5XFAD x Pyk2 −/− mice ( Fig. 4E-F) . Although hippocampal plaque load was similar in the two genotypes in CA1 and DG, the number of plaques was decreased in CA3 of 5XFAD x Pyk2 −/− mice as compared to 5XFAD littermates.
Hippocampal levels of glial fibrillary acidic protein (GFAP), an index of astrogliosis, were similar in WT and Pyk2 −/− mice and were increased in both 5XFAD and 5XFAD x Pyk2 −/− mice ( Fig. 4G-H) . In summary, the absence of Pyk2 did not further modify the synaptic markers, the amyloid plaques or astrogliosis in 5XFAD mice, except for a decrease in the number of plaques in CA3. Control is provided by incubation with a single antibody, which did not generate specific signal, whereas with the two antibodies an amplification appears as red dots indicating a close proximity of the two proteins. Nuclei are stained in blue with DAPI. Left panels, low magnification confocal images. Scale bar 50 μm. Right panels, higher magnification of Pyk2/β-amyloid interaction in boxed areas in the left panels. Scale bar 20 μm.
Pyk2 overexpression in dorsal hippocampus partially improves the behavioral phenotype of 5XFAD mice
Since the absence of Pyk2 did not markedly modify the phenotype of 5XFAD mice, it was unlikely that it played a necessary role in the pathogenesis in this model. We therefore hypothesized that, on the contrary, the functional Pyk2 deficit observed in 5XFAD mice might be involved in their phenotype. To test this hypothesis, since there is no means to stimulate Pyk2 directly, we decided to increase its expression levels. Eight-month-old WT and 5XFAD mice received in the dorsal hippocampus a bilateral stereotactic injection of AAV expressing Pyk2 (5XFAD/Pyk2 mice) or GFP (WT/GFP and 5XFAD/GFP), as a control (Fig. 5A) . Three weeks later, Pyk2 protein levels increased in 5XFAD/ Pyk2 mice as compared to WT/GFP and 5XFAD/GFP mice ( Fig. 5B-C) . The overall increase in total hippocampal Pyk2 levels was 73% and the increase in pTyr402-Pyk2 levels was 51%, sufficient to restore its levels slightly above those in WT/GFP controls (Fig. 3B-D) . We thus, expected to rescue autophosphorylation-dependent functions of Pyk2. We then carried out the same set of behavioral tests in these mice as in Pyk2 KO mice (see Fig. 3 ). In the elevated plus-maze (Fig. 5E ) the increased time spent in the open arms by 5XFAD/GFP mice, compared with WT/GFP mice, was corrected in 5XFAD/Pyk2 mice. Locomotor activity in the open field was similar in all groups of AAV-injected mice (Fig. 5F ). In the passive avoidance test no difference was observed between 5XFAD/ GFP and 5XFAD/Pyk2 mice (Fig. 5G) , showing that, as expected, overexpression of Pyk2 in the hippocampus was not sufficient to restore the associative memory evaluated in this paradigm that also involves other brain regions. As observed above (Fig. 3C) , the three groups of mice did not display any deficit in short-term memory in the novel object recognition test (Fig. 5H) . However, the deficit in long-term memory observed in 5XFAD/GFP mice, as compared to WT/GFP, was restored in 5XFAD/Pyk2 mice (Fig. 5I) . Thus, behavioral evaluation showed that overexpression of Pyk2 in the dorsal hippocampus of 5XFAD mice rescued some deficits including impairment in long-term memory in the novel object recognition test and aberrant performance in the elevated plus-maze.
Pyk2 overexpression in dorsal hippocampus increases the number of plaques but rescues the loss of synaptic markers in CA1 of 5XFAD mice
To test whether Pyk2 overexpression in the hippocampus modified β-amyloidosis we counted the number of Aβ-immunofluorescent plaques in the hippocampus in 8-month 5XFAD/GFP and 5XFAD/Pyk2 mice (Fig. 6A, B) . The plaque number in all three regions studied was higher in 5XFAD/Pyk2 than in 5XFAD/GFP mice by 50-60%. In contrast, GFAP levels were increased to similar levels in 5XFAD/GFP and 5XFAD/Pyk2 mice as compared to WT/GFP (Fig. 6C-D) , indicating that astrogliosis was similar in the three groups of mice.
Since the moderate increase in Aβ-plaque load in Pyk2 overexpressing mice contrasted with the partial behavioral improvement, we studied possible improvements of other parameters, focusing on synaptic markers. We examined the PSD-95-immunoreactive and synaptophysin-immunoreactive puncta (post-and pre-synaptic markers, respectively), which are an indication of the number of synapses and are decreased in 5XFAD mice in correlation with cognitive decline (Grinan-Ferre et al., 2016; Hongpaisan et al., 2011; Shao et al., 2011) . We analyzed these two markers in CA1 stratum radiatum of 8-month mice. As expected and as observed above for mice from the same genotypes (see Fig. 4A-D) , the number of PSD-95-positive and synaptophysin-positive puncta was decreased in 5XFAD/GFP as compared to WT/GFP mice ( Fig. 6E-H) . The PSD-95 decrease was rescued in 5XFAD/Pyk2 mice and the synaptophysin alteration was partly corrected (Fig. 6F, H) . These results suggest that the behavioral improvement observed in 5XFAD mice following hippocampal overexpression A. Giralt et al. Experimental Neurology 307 (2018) 62-73 of Pyk2 was accompanied by an improvement in the number of synapses revealed by both pre-and post-synaptic markers.
Role of Pyk2 in Src cleavage in 5XFAD mice
Since Pyk2 phosphorylation on Tyr-402 was decreased in 5XFAD mice, we examined Src-family kinases (SFKs), which are recruited and activated when Pyk2 is autophosphorylated at this residue (Dikic et al., 1996) . We have previously shown that SFKs autophosphorylation is decreased in Pyk2 −/− mice (Giralt et al., 2017) . Here we measured the total amount of Src in the hippocampus of Pyk2 −/− mice by immunoblotting. Src full-length form (66 kDa) was decreased, whereas a 52-kDa fragment, detected by an antibody that recognizes a C-terminal epitope, was increased in Pyk2 +/− and Pyk2 −/− mice (Fig. 7A-B) . Both changes were gene-dosage-dependent (Fig. 7B) . These results on Src contrasted with our previous observations on Fyn, which did not appear to be altered in Pyk2 mutant mice (Giralt et al., 2017) and indicated the existence of a proteolytic cleavage of Src in the absence of Pyk2. Interestingly, a similar 52-kDa cleaved Src with potential neurotoxic properties has been reported following excitotoxic stimuli and ischemia (Hossain et al., 2013) , suggesting a possible pathogenic role. We therefore studied Src in 5XFAD mice as compared to WT and found that the 52-kDa form of Src was also increased (Fig. 7C-D) . We then measured the two forms of Src in WT, Pyk2
, 5XFAD, and double mutant mice (Fig. 7E-F) . In this experiment the decrease in 66-kDa Src was not observed in Pyk2 −/− mice, indicating variability of this parameter. In contrast, the 52-kDa form was reproducibly increased in Pyk2 −/− , 5XFAD, and double mutant mice (Fig. 7E-F) . We repeated this , HolmSidak's test vs WT, ** p < 0.01, *** p < 0.001, n = 5-6 mice per group. experiment in AAV-injected mice and observed again an increase in 52-kDA Src, which was corrected by AAV-mediated Pyk2 expression (Fig. 7D, E) . Taken together these results indicate that a decrease in Pyk2 levels and/or autophosphorylation can trigger the appearance of a shorter form of Src, presumably corresponding to a cleaved form missing the N-terminal fragment, with potentially cytotoxic properties. This fragment may contribute to the consequences of Pyk2 decreased function (autophosphorylation) in the 5XFAD model.
Discussion
Although PTK2B is genetically associated with late onset AD (Lambert et al., 2013; Jiao et al., 2015; Beecham et al., 2014) , we do not know whether and how Pyk2, the tyrosine kinase coded by this gene, is involved in the disease. By crossing 5XFAD mice, a transgenic mouse model that mimics human amyloidogenic pathway alterations (Oakley et al., 2006) , with Pyk2 knockout mice we observed that the absence of Pyk2 did not dramatically alter the neurological phenotype of 5XFAD mice. This showed that Pyk2 is not essential for the deleterious consequences of increased Aβ production. The only difference we detected in comparison to simple 5XFAD mice was a decrease in the number of plaques in CA3, indicating a possible contribution of Pyk2 in their appearance. We did not find any major change in Pyk2 protein levels in cortical or hippocampal samples from human AD patients or in 5XFAD mouse hippocampus. However, in 8-month 5XFAD mice Pyk2 autophosphorylation site, Tyr402, was less phosphorylated than in WT littermates, indicating an alteration of Pyk2 activation. In younger animals (3-month) basal levels of pTyr402-Pyk2 were normal, indicating that Pyk2 autophosphorylation deficit is not a very early alteration. Although the cause of Pyk2 functional deficit in 5XFAD mice is not known, it has been shown that Pyk2 is activated downstream of a complex associating PrPc and mGluR5 glutamate receptors, and that this activation is disrupted by Aβ oligomers (Haas & Strittmatter, 2016) . Such disruption might contribute to Pyk2 functional deficit.
To test whether decreased Pyk2 activity in these mice could contribute to their memory deficit we overexpressed Pyk2 in the dorsal hippocampus and thus corrected the levels of autophosphorylated Pyk2. This strategy improved some aspects of the behavioral phenotype, including performance in the elevated plus-maze and novel object recognition long-term memory. Pyk2 overexpression also improved synaptic alterations which are known to be a major source of AD symptomatology (Pozueta et al., 2013; Sheng et al., 2012; Tu et al., 2014) . Recent evidence shows that Pyk2 plays an important role at hippocampal synapses (Giralt et al., 2017) . Pyk2 is involved in PSD-95 post-synaptic recruitment and clustering (Giralt et al., 2017) , regulates NMDA receptors subunits (Huang et al., 2001; Giralt et al., 2017) and even the 50% Pyk2 decrease observed in heterozygous Pyk2+/− mice is sufficient to markedly alter synaptic properties (Giralt et al., 2017) . The behavioral improvement induced by Pyk2 overexpression in 5XFAD mice was associated with a pronounced reduction of previously . In C-E and G-I post-hoc test was HolmsSidak, * p < 0.05, ** p < 0.01, **** p < 10 A. Giralt et al. Experimental Neurology 307 (2018) 62-73 reported synaptic alterations (Grinan-Ferre et al., 2016; Hongpaisan et al., 2011) , evidenced by the recovery of PSD-95 and synaptophysin clustering. We therefore suggest that Pyk2 functional deficit in 5XFAD mice contributes to the synaptic alterations and that its rescue is an important contribution to Pyk2-induced behavioral improvement. One of the mechanisms possibly linking Pyk2 deficiency with synaptic dysfunction is a deficit in SFK activation. We previously reported a decreased SFK basal autophosphorylation in the hippocampus of Pyk2 knockout mice with no change in total levels of Fyn (Giralt et al., 2017) . We show here that Pyk2 mutant mice display increased levels of a smaller 52-kDa form of Src. This observation is reminiscent of the reported cleavage of Src by calpain, a Ca 2+ -activated protease, which generates ã 52 kDa protein lacking the N-terminal myristoylation site (Hossain et al., 2013) . This truncated Src is generated in vivo following ischemia and has neurotoxic properties (Hossain et al., 2013) . In 5XFAD mice although modifications of full-length Src were not detected, the 52-kDa fragment was increased, and Pyk2 overexpression corrected this alteration, possibly alleviating a toxic effect. It can be therefore hypothesized that this Src fragment could contribute to the impairments in 5XFAD mice. The mechanisms leading to the putative cleavage of Src in Pyk2 mutant and 5XFAD mice are not known and will require further exploration.
Our work reveals the multiple roles that SFKs appear to have in AD models. On the one hand, several studies showed that Fyn inhibition either genetically (Lambert et al., 1998; Pena et al., 2010) (but see (Minami et al., 2012) ) or using pharmacological inhibition of Fyn (Kaufman et al., 2015; Smith et al., 2018) improves their phenotype, possibly in relation with a contribution of Fyn to Tau pathology at the somatodendritic level (Kaufman et al., 2015; Li & Gotz, 2017; Ittner et al., 2010) . On the other hand, our results indicate that a deficit in SFK activation, possibly at the synaptic level, may also contribute to functional deficits in Pyk2 mutant mice and in 5XFAD mice. A toxic Src breakdown product may have an additional negative role. Thus Pyk2 through its capacity to recruit and activate SFKs in response to neuronal activity is strategically located to modulate the balance between their various implications. Importantly, this role of Pyk2 deficit in 5XFAD mice phenotype fully agrees with the observation that inhibition of STEP, a phosphatase active on Pyk2 (Xu et al., 2012) , increases Pyk2 phosphorylation and improves the behavior of 3xTg-AD mice .
The complexity of the role of Pyk2 and SFKs in the context of AD is also illustrated by their possible contribution to amyloidogenesis. SFKs have been reported to contribute to Aβ increase production (Dunning Gianni et al., 2003) . In our study manipulating Pyk2 levels in vivo had only moderate effects on the number plaques, which were opposite to the functional and synaptic improvements. In the absence of Pyk2, we found a decrease in amyloid plaques in CA3, whereas Pyk2 overexpression in 5XFAD mice slightly increased plaque number throughout the hippocampus. These results suggest that Pyk2 might contribute to plaque formation, possibly through a modulation of Aβ production. In this respect it is interesting to note that Pyk2-and Aβ-like immunoreactivities colocalized in the neuropil but not in plaques, indicating a proximity of Pyk2 with sites of Aβ production. In our experimental conditions, however, the changes in plaque numbers were in opposite direction to the observed behavioral improvement, suggesting they did not play a major role in the overall effect of Pyk2 in the 5XFAD model. It should be noted that although a decrease in plaque number is usually correlated with behavioral improvement in 5XFAD mice (Antonios et al., 2015; Bhattacharya et al., 2014; MacPherson et al., 2017; Aytan et al., 2013) , the role of plaques by themselves in the disease is disputed (Castellani et al., 2009; Cohen et al., 2009) . It is also possible that the strong effect of mutations responsible for Aβ production in 5XFAD mice partly occluded the contribution of Pyk2 to amyloid production and revealed the prominent impact of Pyk2 deficit in synaptic dysfunction.
In summary, we have explored the potential role of Pyk2 in a transgenic amyloid mouse model of AD. Our results do not support a strong positive or negative role of Pyk2 in this model of the disease. In contrast, they indicate a functional deficit of Pyk2 that is likely to contribute to synaptic alterations and to generation of a potentially toxic Src fragment. In 5XFAD mice, enhancing Pyk2 function by overexpression corrects these various alterations and has an overall beneficial effect on behavior, suggesting that restoring Pyk2 might be a useful target in AD.
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